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Open access under CCPrimary sclerosing cholangitis (PSC) represents a chronic chole-
static liver disease with ﬁbroobliterative sclerosis of intra- and/or
extrahepatic bile ducts, eventually leading to biliary cirrhosis.
The association with human leukocyte antigen (HLA) and non-HLA
haplotypes and the presence of autoantibodies in sera of PSC
patients support a crucial role for immune-mediated mechanisms
in the initiation and progression of PSC. The strong clinical asso-
ciation between PSC and inﬂammatory bowel diseases led to
intriguing pathogenetic concepts, in which the inﬂamed gut with
translocation of bacterial products and homing of gut-primed
memory T lymphocytes via aberrantly expressed adhesion mole-
cules plays a fundamental role. Genetically or chemically modiﬁed
bile composition was shown to induce sclerosing cholangitis and
liver ﬁbrosis in a number of animal models ("toxic bile concept").
The potential role of vascular injury with ischemia of bile duct
epithelium cells in the development of sclerosing cholangitis is
supported by animal models of endothelial cell injury showing
close morphological similarities with human PSC.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Aetiology and pathogenesis of PSC still pose many unresolved questions and remain a scientiﬁc and
clinical challenge. The lack of a generally accepted pathogenetic concept might be linked to several41; fax: þ43 (0) 1 40400 4735.
c.at (M. Trauner).
 BY-NC-ND license.
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allowing early detection and detailed follow-up studies of early PSC, (iii) the fact that bile ducts are
difﬁcult to investigate and directly access without invasive tests such as endoscopy or liver biopsy, and
(iv) weaknesses of currently used deﬁnitions and diagnostic standards for PSC. Consequently PSC
probably represents an umbrella term, since besides “classical” PSC various different etiologies may
cause secondary sclerosing cholangitis (SSC) or cholangiopathies “mimicking” PSC and which in some
cases may have been previously classiﬁed as PSC. The diagnosis of PSC requires ﬁrm exclusion of
secondary causes. Thus, PSC as an own disease entity is as per deﬁnition increasingly fragmenting/
splitting up into secondary forms and subtypes as identiﬁable causes emerge; one recent example for
this development may be the IgG4-positive forms of cholangitis. However, most likely PSC represents
amultifactorial disease, inwhich the inﬂuence of a singlemechanismmay vary considerably among the
different clinical subtypes (e.g. PSCwith andwithout IBD). Evidence supporting a genetic predisposition
for PSC is derived from an obvious familial and geographic clustering with high prevalence in Northern
countries (e.g. Norway, Sweden) compared to Southern Europe and Asia [1]. This clustering suggests
that combined genetic/environmental factors might be required for PSC development (e.g. selen and
vitamin D deﬁciency). Thus, PSC is likely to be caused by interplay of multiple genetic variants and
environmental factors [2]. However, these complex interactions are still not entirely understood. Based
on its associations with HLA halplotypes, autoimmune diseases and the presence of inﬂammatory
bowel disease (IBD), especially ulcerative colitis (UC) in the majority of PSC patients, immunopatho-
genetic mechanisms have been implicated in PSC pathogenesis [3]. Although the mechanistic links
between PSC and IBD are still not satisfactorily explained, this association of PSC suggests a common
pathogenetic agent or common inﬂammatory pathway in the pathogenesis of both diseases. However,
PSC cannot be considered as a classical autoimmune disease, as it occurs with a 2:1male predominance
and lacks characteristic response to immunosuppressants [4]. Thus, PSC has recently been re-classiﬁed
as an immune-mediated disease comparable to UC. Fig.1 illustrates human data and clues derived from
animalmodels that are currently implicated in PSC pathogenesis. The aimof this review is to summarize
the current knowledge and hypothetical models implicated in the pathogenesis of PSC.
Genetic background/susceptibility
Following the identiﬁcation of certain HLA variants (i.e. HLA-DR3 and HLA-B8) in PSC patients in
1982 [5] the genetic architecture of PSC patients attracted increasing interest. Accordingly, studies on
PSC heritability have shown that ﬁrst-degree relatives of PSC patients have a disease prevalence of
0.7%, representing a nearly 100-fold increased risk of developing PSC compared to the general pop-
ulation [6]. In siblings the prevalence even reaches 1.5% [6,7]. Taken together, these epidemiologic data
with the distinct geographic occurrence of PSC (high prevalence in Northern countries compared with
Southern Europe and Asia) [1] emphasize the role of genetic factors in PSC pathogenesis. Recently,
strong evidence for genetic susceptibility was derived from genome-wide association analyses (GWA)
showing strong associations with a subset of HLA and non-HLA genes involved in bile homeostasis and
associated with regulatory inﬂammatory pathways as key components of the genetic architecture in
PSC patients (listed in Table 1) [8].
HLA-type genes and PSC
The HLA complex is located on the short arm of chromosome 6, stretches across 7.6 million base
pairs (bp) of DNA and contains 252 expressed protein-coding genes, of which w30% are related to
immunological functions [9]. Whereas HLA class I molecules are expressed on all nucleated cells,
present intracellular antigens to CD8þ lymphocytes and serve as ligands for inhibitory killer
immunoglobulin-like receptors (KIRs) on natural killer (NK) cells as well as gd T-lymphocytes, HLA
class II molecules are expressed on antigen presenting cells and present exogenous antigens to CD4þ
lymphocytes [10]. Early studies on PSC HLA association from Norway and the UK identiﬁed HLA-DR3
(DRB1*0301) and HLA-B8 (HLA-B*0801) haplotypes as important susceptibility markers [5,11]. While
subsequent studies from Finland [12], Australia [13] and recently from Norway [8] conﬁrmed these
data, no associations with any HLA-B haplotype were found in an Italian Study [14] and in Brazil [15]
studies. In addition, the HLA-A1 allele [16], the HLA-C7 [17], themajor histocompatibility complex class I
Fig. 1. Shows a comparative illustration of potential pathogenetic factors in human PSC (left) and clues derived from animal models
(right).
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promoter -308 A allele [14,20] were identiﬁed to be associated with PSC susceptibility. Susceptibility
alleles encoded in the HLA class II haplotype include DRB1*0301 (DR3) and DRB1*13 (DR6) [21,22]. In
a comprehensive study from ﬁve different European countries (UK, Italy, Norway, Spain and Sweden),
PSC was positively associated with three different HLA class II haplotypes, the DRB1*03, DQA1*0501,
DQB1*02, the DRB1*15, DQA1*0102, DQB1*0602 and the DRB1*13, DQA1*0103, DQB1*0603 haplotypes
[21]. A negative association was found for the DRB1*04, DQA1*03, DQB1*0302 haplotype. The highest
relative risk to develop PSC is conferred by the DRB1*03, DQA1*0501, DQB1*02 homozygous genotype
[21]. Approximately half of all PSC patients in Norway and Sweden carry at least one of these haplo-
types [23], whereas none of these haplotype associations was detected in PSC patients from Italy and
only the DRB1*13, DQA1*0103, DQB1*0603 was present in PSC patients from Brazil [14,15,21,23]. These
data underscore the considerable heterogeneity in both HLA classes of different populations and may
contribute to the observed differences.
Non-HLA-type genes in PSC
Speciﬁc combinations of HLA class I and killer immunoglobulin-like receptor (KIR) alleles have been
implicated in autoimmunity, tumour surveillance and viral diseases [23]. KIRs function as NK cell
receptors which bind HLA class I molecules whichmay activate or constitutively inhibit NK cell activity.
However, the exact mechanisms how KIR/HLA class I ligand genotypes inﬂuence susceptibility to
autoimmune diseases are not entirely clear [24]. Imbalance of KIR and/or HLA class I ligands resulting
in reduced inhibition or increased activation might be pivotal in PSC pathogenesis [10,25]. Possible
interactions between HLA class I alleles and KIR genes were studied in 365 Scandinavian PSC patients
and 368 healthy controls [25] showing reduced frequency of ligands, HLA-Bw4 and HLA-C2, for the
Table 1
Associations of PSC with HLA and non-HLA haplotypes.
Haplotype RR/Impact Ref.
HLA associations
B8-MICA*008-TNFA*2-DRB3*0101-DRB1*0301-DQB1*0201 2.69 [16]
DRB3*0101-DRB1*1301-DQA1*0103-DQB1*0603 3.8 [16]
MICA*008-DRB5*0101-DRB1*1501-DQA1*0102-DQB1*0602 1.52 [16]
MICA*008 homozygosity 5.01 [18]
DRB4*0103-DRB1*0401-DQA1*03-DQB1*0302 0.26 [16]
DRB4*0103-DRB1*0701-DQA1*0201-DQB1*0303 0.15 [16]
MICA*002 0.12 [18]
Non-HLA associatons
ICAM-1 0.26 [29]
CCR5D32 n.d./protective [35]
3.17 [34]
no association [36]
CFTR 0.25 [107]
TGR5
SNP rs12612347 1.26 [8]
SNP rs11554825 1.14 [38]
PXR/SXR n.d./modiﬁer gene [50]
MDR3 n.d./weak association [99]
GPC5/GPC6 0.77 [8]
MMP-1 n.d./no association [113]
MMP-3 n.d./no association [113]
MMP3 alelle 5 1.78 [114]
Abbreviations: CCR5D32, chemokine receptor 5 with 32-base pair deletion; CFTR, cystic ﬁbrosis transmembrane conductance
regulator; GPC5/6, glypican 5/6; HLA, human leukocyte antigen; ICAM-1, intercellular adhesion molecule-1; MDR, multidrug
resistance; MICA, major histocompatibility complex class I chain-related A; MMP, matrix metalloproteinase; n.d., not deter-
mined; PXR, pregnane X receptor; SNP, single-nucleotide polymorphism; SXR, steroid and xenobiotic receptor; TGR5, G-protein
coupled bile acid receptor-1.
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suppression might be critical for PSC susceptibility. Additional evidence for a central role of HLA-
related NK cell activity in PSC was derived from studies on MIC genes, namely MICA and MICB that
can directly activate NK cells receptors [18]. A strong protective effect was found forMICA*002 allele in
PSC patients from the UK [18]. In a Norwegian study, MICA5.1 and MICB24 alleles were signiﬁcantly
increased in PSC patients [19]. However, when stratiﬁed for DR3-positivity, the association of these
markers was no longer evident. This means that bothMICA5.1 andMICB24markers are associated with
PSC only in the presence of HLA-B8 and -DR3 haplotypes and vice versa. Therefore, the authors sug-
gested an association of the extended B8-MICA5.1-MICB24-DR3 haplotype with PSC [19].
Approximately 80% of PSC patients in Northern Europe have IBD, especially UC [1], suggesting
shared inﬂammatory pathways based on common susceptibility genes. In contrast to PSC, the asso-
ciation between UC and HLAwas weak and inconsistent [23]. A direct comparison of Scandinavian PSC
patients with Norwegian UC patients showed distinct HLA associations [26]. No signiﬁcant differences
were noted between PSC patients with concurrent UC and PSC patients without IBD, suggesting
different HLA associated genetic susceptibility. Furthermore, these data support the assumption of
a distinct UC phenotype in PSC patients [26]. Taken together, appropriate interpretations of HLA-
associations in PSC seem to be extremely difﬁcult.
Intercellular adhesion molecule-1 (ICAM-1, CD54) gene polymorphisms have been implicated in the
susceptibility to various inﬂammatory diseases including IBD. As adhesion molecule and ligand for
lymphocyte function associated-1 (LFA-1), ICAM-1 mediates leukocyte adhesion during immune
responses and transendothelial migration of neutrophils and T-cell activation [23]. In PSC, ICAM-1
shows expression on proliferating bile ducts in late stage PSC [27] and serum levels of soluble ICAM-
1 are increased [28]. The polymorphism K469E in exon 6 causes a change from glutamic acid to
lysine in the Ig-like domain of ICAM-1 on biliary epithelial cells affecting interactions between LFA-1
and B-lymphocytes [29]. However data on the frequency and effects of this polymorphism in PSC
patients are conﬂicting [29,30]. In addition, members of the chemokine family, including the CC-type
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(CCR5-Δ32) results in a frame shift mutation and encodes a non-functioning receptor [31]. Population-
based studies showed conﬂicting data ranging from a protective to adverse effect of the CCR5Δ32
polymorphism on PSC susceptibility [32–35]. The largest study covering 363 Scandinavian PSC
patients, however, failed to show any involvement of CCR5-Δ32 in either PSC susceptibility or
progression [36].
Based on its dual function in biliary bicarbonate secretion and anti-inﬂammatory effects in
macrophage/Kupffer cells [37] the G protein-coupled bile acid receptor 1 (GPBAR1) TGR5 has been
implicated in PSC pathogenesis. Recently, signiﬁcant associations for one exonic single-nucleotide
polymorphism of the TGR5 gene were found for both PSC and UC [8,38]. However, the functional
role of TGR5 as a potential candidate gene in both diseases conditions is still unclear and requires
further mechanistic studies [38]. Interestingly, the expression of TGR5 in colon shares the same right-
sided predominance as reported for PSC-UC [39].
The multidrug-resistance gene 1 (MDR1) gene represents an interesting candidate for PSC suscep-
tibility due to its role as membrane transport protein mediating efﬂux of a wide range of xenobiotics
and toxins [40] and MDR1 gene variants may be associated with IBD disease progression and severity
[41]. However, no signiﬁcant associations could be identiﬁed in PSC or different IBD studies [42,43].
The steroid and xenobiotic receptor (SXR), and its rodent analogue pregnane X receptor (PXR), is
predominantly expressed in liver and intestine [44]. SXR regulates proteins pivotal for drug transport
and metabolism, such as cytochrome P450 3A4 (CYP3A4) and drug efﬂux pumps like MDR1 p-glyco-
protein [45]. Moreover, SXR serves as a bile acid receptor and regulator of bile acid and cholesterol
homeostasis [46]. It may be worthwhile to study SXR gene polymorphisms in PSC and IBD since the
expression of various enzymes and bile acid transporters under control of SXR has shown to be affected
[47,48]. However, the reported associations between SXR variants and PSC/IBD are rather weak [49,50].
Pathogenetic clues from the association between IBD and PSC
Despite the description of PSC-UC association more than 40 years ago by Smith and Loe [51] this
interesting clinical observation is still not entirely understood. Most important, the activity of IBD does
not correlate with the severity of PSC and vice versa [52]. As such, PSC can occur several years after
colectomy and conversely IBD may even develop years after liver transplantation [52–54]. In contrast
and interestingly enough, comparative data on the impact of pre-transplant colectomy and post-
transplant colitis activity on PSC recurrence in the PSC-IBD patients identiﬁed the absence of active
colitis after liver transplantation as a protective factor against PSC recurrence [55]. The comparison of
liver-transplanted and non-transplanted PSC-IBD patients revealed a favourable impact of liver
transplantation on clinical and histological IBD activity [56]. These clinical associations between PSC
and IBD stimulated several intriguing pathogenetic models.
The leaky gut hypothesis
Translocation of bacteria or bacterial components and products entering the portal-venous system
via an increased intestinal permeability resulting from an inﬂamed gut with concomitant induction of
an inﬂammatory reaction concentrated to portal ﬁelds is frequently referred to as the “leaky gut
hypothesis” [3]. Bacteria may penetrate the damaged mucosal layer during acute inﬂammatory
episodes, enter the liver and consequently stimulate release of chemokines/cytokines by Kupffer cells
and macrophages leading to cholangitis and resulting wound healing process with concentric peri-
ductal ﬁbrosis [3, 4]. Experimental evidence derived from animal models suggest that small intestinal
bacterial overgrowth and infusion of bacterial antigens into the portal circulation can indeed lead to
hepatic inﬂammation with at least some characteristic features of human PSC (i.e. pericholangitis)
[57–59]. Small intestinal bacterial overgrowth in genetically susceptible rats induces macroscopic and
microscopic features similar to human PSC [57]. Components of anaerobic bacteria, such as
peptidoglycan-polysaccharides, are likely to be mainly responsible for these morphological changes. In
addition, administration of a chemotactic peptide produced by E. coli into the colon of rats with
acetate-induced colitis induced hepatic lesions reminiscent of PSC [58]. Therefore it was tempting to
hypothesize that in genetically susceptible individuals, bacterial antigens function asmolecular mimics
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no direct clinical evidence for increased portal vein bacteraemia in PSC/IBD patients [60,61]. Moreover,
potential technical drawbacks and pitfalls of such studies have to be considered. A Scandinavian
investigation on intestinal permeability and small bowel bacterial ﬂora in PSC patients identiﬁed
bacterial overgrowth in only one out of 22 PSC cases and comparable intestinal permeability in PSC and
control patients [62]. Indirect evidence against this concept may also be drawn from negative studies
testing antibiotics in PSC patients [63] and more recently a randomized placebo-controlled trial
evaluating the effects of metronidazole plus ursodeoxycholic acid on PSC progression [64]. Taken
together, these ﬁndings at least in part dismiss a major impact for increased intestinal permeability,
bacterial overgrowth or translocation in PSC pathogenesis [62]. Nevertheless, translocation of intes-
tinal bacteria/bacterial products may be episodic, hard to detect and still accelerate disease progression
[65]. Future studies will also have to determine the role of the gut microbiome in PSC pathogenesis.
Gut lymphocyte homing hypothesis
The observation that PSC frequently runs a course independent of IBD activity led to the idea that
CCR9þ a4b7þ memory T lymphocytes primed in the inﬂamed gut may persist as long-lived memory
cells, undergo enterohepatic circulation with the possibility to trigger portal inﬂammation in PSC via
aberrantly expressed adhesionmolecules in liver and gut [4,66]. This is currently referred to as the “gut
lymphocyte homing hypothesis” [66]. Studies on the expression pattern of adhesion molecules and
characterization on the inﬂammatory inﬁltrate argue at least inpart for such a concept in several points:
(i) PSC livers show ectopic expression of the adhesion molecule mucosal addressin cell adhesion
molecule-1 (MAdCAM-1) which is normally restricted to the gut [67], (ii) in IBD, the intestinal
expression of the vascular adhesionprotein-1 (VAP-1) expression is signiﬁcantly increased [68], and (iii)
the inability of liverdentritic cells (DCs) to imprint gut tropism [67]. However, the presence ofMAdCAM-
1 staining in the portal veins could also be detected in other chronic liver diseases, including autoim-
mune hepatitis, primary biliary cirrhosis and chronic hepatitis C [69]. Thus, MAdCAM-1 expression
might rather be a consequence than a cause of inﬂammation in PSC. Grant’s hypothesis [66] provides no
explanation of PSC cases without IBD or why some IBD patients suffer from PSC while others do not.
Taken together, there is a clear clinical association between PSC and IBD, although the pathogenetic
link still remains to be unsatisfactorily explained.
Cellular immune response in PSC
The deﬁnition and characterization of the cellular immune response in PSC widely depends on the
availability of liver tissue suitable for morphological studies including immunohistochemical methods.
As far as studying and interpreting of liver samples in PSC patients is concerned the following general
problems have to be taken into consideration: (i) a sampling error due to a large intrahepatic hetero-
geneity in PSC is most likely, (ii) large ducts are usually not seen and efﬁciently evident on liver biopsy,
(iii) the lack of sufﬁcient numbers of liver tissue samples from early stage patients, and (iv) frequently
histology – if performed at all due to its low diagnostic value in PSC - is done in late stage disease with
advanced ﬁbrosis or cirrhosis. Thus, liver biopsy may rather reveal the footprints of the disease rather
than early primary events of PSC which would most probably offer more clues to pathogenesis.
Early histological changes in PSC include a diffusemixed inﬂammatory cell inﬁltrate of lymphocytes,
plasma cells and neutrophils that are most intense around the bile ducts [70]. As the disease advances,
the inﬂammation has a tendency to subside, leaving a combination of portal ﬁbrosis and oedema, focal
ductular reaction and progressive reduction in the number of bile ducts. The typical histological picture
of end-stage-PSC is composed of ﬁbro-obliterative bile duct lesions, characterized by an “onion-skin”
type of periductalﬁbrosis ofmedium-sized or larger bile ducts, with degeneration and atrophy of biliary
epithelial cells [70]. Notably, since this morphological features can only be considered as characteristic
but not PSC-speciﬁc, the histological distinction between PSC and SSC may be extremely difﬁcult or
even impossible. This probably also reﬂects the limited reaction pattern of bile ducts.
Based on histological ﬁndings, the hepatic innate immune response has been considered to be
a primary inciting event in the pathogenesis of PSC. Accordingly, it is tempting to speculate that PSC
developmentmight be initiatedbyexogenous triggers suchasbacteria orpathogen-associatedmolecular
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inﬂammatorycells, such asmacrophages, dentritic cells (DCs), andNKcells are activated throughpattern
recognition receptors, secrete cytokines and perpetuate inﬂammatory reaction by activation of NK cells
through IL-12 and recruitment of lymphocytes via TNF-a, IL-1b and CXCL8 [23]. Biliary epithelial cells
(BECs) have an active role in propagating the proinﬂammatory and proﬁbrotic response. Under physi-
ological conditions BECs express onlyHLAclass I andnot class IImolecules. In PSC, aberrant expressionof
HLA classmoleculeswas observed [4,71]. In addition, BECs can acquire a kind of reactive phenotypewith
overexpression of adhesion molecules and the ability to produce and secrete proinﬂammatory and
chemotactic cytokines and growth factors, further accelerating the inﬂammatory process [72].
Adaptive immunity is characterized by responses to speciﬁc nonself-processed peptide antigens or
auto-antigens presented via MHC class I and II molecules on antigen presenting cells to T-cell receptors
(TCR) [3,73]. In PSC, a predominant T cell inﬁltrate in the portal area can be found. However, the
composition of T cells (CD4/CD8 ratio) in PSC patients shows considerable inconsistencies in different
studies [74,75] which might reﬂect the distribution of T cell subsets within the liver, in which CD4 cells
are seen more commonly in the portal tracts and CD8 cells predominate in areas of lobular hepatitis
[76]. TCRs consist of four disulphide linked polypeptides, namely ab and gd, and determine the
speciﬁcity of T cells [4]. Increased proportions of gdþ T cells have been found in PSC patients, although
their signiﬁcance in disease development is still unknown [77].
Sclerosing cholangitis of the intra- and extrahepatic bile ducts can be observed in patients with
autoimmune pancreatitis (AIP), causing still some diagnostic confusionwith PSC due to the lack of clear
cut diagnostic criteria. Accordingly, sclerosing cholangitis associated with AIP is now referred to as
IgG4-related sclerosing cholangitis (IAC) [78,79]. IAC is characterized by a steroid-responsive multi-
system ﬁbroinﬂammatory disorder in which affected organs have a lymphoplasmocytic inﬁltrate rich
in IgG4-positive cells and has recently become widely recognized as distinct clinical entity from
classical PSC [80]. Of interest, 10–15% of PSC patients have been shown to have elevated IgG4 in serum
and nearly 50%may show IgG4 positive plasma cells on liver biopsy [81]. The fact that in themajority of
these IAC cases corticosteroid therapy signiﬁcantly improves both the pancreatic and the biliary
ﬁndings supports the idea that these lesions are not typical PSC [80]. So far, however, it is unclear
whether IgG4 may also play a role in the pathobiology of classic PSC.
The hypothesis of autoimmune pathogenesis of PSC is supported by the presence of various auto-
antibodies, including perinuclear antineutrophil cytoplasmic antibodies (p-ANCA) or nuclear anti-
bodies (ANA) in the sera of PSC patients [82]. More than 80% of PSC patients show atypical anti-
neutrophil cytoplasmic antibodies (ANCA) [83]. However, due to the overlap with autoimmune
hepatitis [83] and the missing correlation with PSC activity [84], ANCA are of limited clinical value as
diagnostic or therapy tailoring tool in PSC patients. In general, two distinct staining patterns of ANCA
can be distinguished, the cytoplasmic (c-ANCA) and the perinuclear (p-ANCA) which can be further
subdivided into so-called classical p-ANCA or atypical p-ANCA [85]. The latter appear to be speciﬁc for
PSC with predominant IgG classes of antibodies. The question of the autoantigen to which atypical
p-ANCA in PSC are react, remains to be determined. A number of proteins, including azurocidin,
bactericidal/permeability increasing protein, cathepsin G, elastase and lactoferrin [86–89] have been
suggested as potential candidates. However, only in a minority of PSC patients, reactivity to these
antigens has been found [85]. Recently, the tubulin beta isoform 5 present in human neutrophils and
the bacterial cell division protein FtsZ that is present in nearly all bacteria of the intestinal microﬂora,
have been identiﬁed [85]. According to the authors, this might reﬂect the basis for molecular mimicry
in which autoantibodies triggered by a bacterial infection cross-react and inhibit normal immune cell
function [23,85]. Cholangiocytes are suggested to be the primary targets of immune attack, since
autoantibodies directed against surface antigens on BECs were found in a signiﬁcantly higher number
of PSC compared with PBC, AIH and control patients [90]. Binding of antibodies to the BEC-antigens
initiates ERK1/2 signalling and upregulation of toll-like receptors (TLR), which induces the produc-
tion of cytokines/chemokines by BECs, leading to recruitment of inﬂammatory cells and initiation and
perpetuation of the inﬂammatory process [91].
Taken together, the general problem of deﬁning cell response in PSC can be attributed to the difﬁcult
detection of early PSC lesions in representative tissues. Novel imaging strategies as well as novel serum
markers for inﬂammatory response in PSC patients are therefore warranted.
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To date, no ideal animal model has been established that shows all characteristic of human PSC [59].
Animal models can be classiﬁed into the following groups (summarized in Table 2): (i) chemically-
induced cholangitis, (ii) knock-out mouse models, (iii) cholangitis induced by infectious agents, (iv)
models of experimental biliary obstruction, (v) models involving enteric bacterial cell-wall compo-
nents or colitis and (vi) models of primary biliary epithelial and endothelial cell injury [59].
The genetic modiﬁcation of bile compositionwas shown to induce sclerosing cholangitis and biliary
ﬁbrosis via the development of toxic bile in a number of animal models [92–96]. Mice with targeted
disruption of the Mdr2 (Abcb4) gene encoding a canalicular phospholipid ﬂippase spontaneously
develop cholangitis and typical onionskin type periductal ﬁbrosis mirroring some of the key features of
human PSC [92,93]. The development of these morphological changes is most likely due to defective
biliary phospholipid secretion resulting in an increased concentration of free non-micellar bile acid [92].
However, the following limitations of theMdr2/mousemodel have to be considered: (i)Mdr2/miceTable 2
Animal models of sclerosing cholangitis.
Animal model Species Proposed pathophysiological
mechanisms of SC
Ref.
Chemically induced cholangitis
TNBS Sprague–Dawley, Lewis rats TNBS haptenization, multifactorial? [115, 116]
ANIT Sprague–Dawley rats ANIT-induced BEC-injury? [117]
DDC Swiss albino mice porphyrogenic properties of DDC [108]
LCA Swiss albino mice physiochemical properties of LCA [109]
Knockout mouse models
Mdr2/ FVB/N toxic bile [93]
Cftr/ C57BL/6J toxic bile [94]
fch/fch BALB/c PP accumulation [95, 96]
Infectious agents
Cryptosporidium parvum BALB/c nu/nu, BALB/c SCID,
C57BL76-SCID, NIH-III nu/nu
CD40/, IFNg/, CD154/,
CD40-CD154/, Tnfsf5/,
Tnfrsf1a/, Tnfrsf1b/,
Tnfrsf1a/1b/,
Tnfsf5-Tnfrsf1a/,
Tnfsf5-Tnfrsf1b/,
Tnfsf5-Tnfrsf1a/1b/,
CD40-Tnfrsf1a/1b/
dysfunctional T cell response to
exogenous trigger
[118–120]
Helicobacter hepaticus A/JCr, C3H/HeNCr,
C57BL/6NCr, A/J
unknown [121]
Experimental biliary obstruction C57BL/6J toxic bile, [ biliary pressure [122]
Models involving enteric
bacterial cell-wall
components or colitis
SBBO Lewis and Wistar rats [54]
PG-PS Lewis rats [ intestinal permeability [58]
fMLT Wistar rats [58]
DSS CD-1 mice [123]
TNBS þ ANIT Spraque-Dawley rats [124]
Models of biliary epithelial
and endothelial cell injury
Experimental GVHD BALB/c BEC injury [111]
TNBS Lewis rats endothelial cell injury [125]
Complete hepatic arterial
deprivation
Wistar rats hypoxia, ischemia of BECs [126]
Abbreviations: ANIT, alpha-naphthylisothiocyanate; BEC, biliary epithelial cell; Cftr, cystic ﬁbrosis transmembrane conductance
regulator; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; DSS, dextrane sodium sulfate; fch, ferrochelatase; fMLT, N-formyl L-
methionine L-leucin L-tyrosine; GVHD, graft-versus-host disease; LCA, lithocholic acid; Mdr2, multidrug resistance protein-2;
PG-PS, peptidoglycan-polysaccharide; PP, protoporphyrin; SBBO, small bowel bacterial overgrowth; SCID, severe combined
immunodeﬁciency; SFBL, self-ﬁlling blind loop; TNBS, 2,4,5-trinitrobenzene sulfonic acid.
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elevated bilirubinwas shown to be normal [97], and (iii) the role ofMDR3 variants in the pathogenesis of
PSC is still unclear [98]. In a study comparing the genetic variability and haplotype structure ofMDR3 in
PSC patients with healthy controls, no difference in the total number of MDR3 variants or in the allele
frequency was observed [99]. However, one heterozygousMDR3mutationwas shown to be speciﬁc for
PSC and oneMDR3haplotypewasmore frequently observed in the PSC group [99]. Although the current
data do not support a major role for MDR3 in PSC pathogenesis, gene variants could still play an
important role by altering bile composition and thereby the aggressiveness of bile, which could inﬂu-
ence the secondary response to any primary (e.g., immune-mediated or ischemic) bile duct injury and
consequently disease course [98]. However, certain MDR3 haplotypes could be associated with sub-
phenotypes of the disease [99]. Since PSC includes a heterogeneous group of patients with variable
pathogenetic background, MDR3 variations should be investigated in selected PSC subgroups, such as
thosewith small duct PSC [98]. Notably, DSS-induced colitis in heterozygousMdr2þ/mice as a “second
hit” induced onlymild portal inﬂammationbutnot the full-blownpicture of sclerosing cholangitis [100].
Mice harbouring a mutation of exon 10 of the cystic ﬁbrosis (CF) transmembrane conductance
regulator (CFTR) gene were shown to develop focal cholangitis and biliary cirrhosis within one year of
age [94]. However, other investigators identiﬁed a predominant intestinal phenotype in Cftr/ mice
with mild or no pathological changes in other organs [101–104]. This is consistent with lacking
association of CFTR variants in PSC patients [105]. Intriguingly, recent studies suggest that loss of CFTR
affects BEC innate immunity and causes TLR4–NF–kB-mediated inﬂammation [106]. Paradoxically,
a recent study investigating the inﬂuence of CFTR polymorphisms on the development and evolution of
PSC identiﬁed the 1540G variant and the TG11-T7 haplotypes to be associated with protection from
PSC, particularly in subjects without IBD [107].
Further evidence for the important role of the bile composition in the development of sclerosing
cholangitis and biliary type of liver ﬁbrosis is derived from animalmodels with chemically-induced bile
composition [108,109]. Feeding of 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) in mice induced
characteristic features of sclerosing cholangitis [108]. Although the exact underlying mechanisms of
DDC-induced cholangitis are unknown, increased porphyrine secretion and induction of a reactive
cholangiocyte phenotype via toxic bile components are implicated in the development of the histo-
logical features in this model. A recent elegant study suggests a pivotal role for impaired micelle
formation and phospholipid secretion also in this model [110].
Feeding of lithocholic acid (LCA) results in the development of bile infarcts, destructive cholangitis,
periductal edema and ﬁbrosis in mice, features that are observed in early-stage PSC [109]. The
morphological changes are most likely linked to the physiochemical properties of LCA (i.e. high
hydrophobicity and lithogenicity) together with obstruction of bile ducts through LCA precipitates
[109]. We think that LCA feeding leads to periductal ﬁbrosis via an efﬂux of “toxic bile” into the portal
ﬁeld and subsequent activation of BECs and periductal myoﬁbroblasts [109]. Due to the short rapid
changes observed in LCA-fed animals, this mouse model is a valid short-term model to study early
changes in the development of sclerosing cholangitis. Strong evidence for the potential role of vascular
injury with subsequent ischemia of BECs in the development of sclerosing cholangitis is provided by
animal models of endothelial cell injury. In a mouse model of experimental graft-versus-host disease
(GVHD) severe cholangitis of intra- and extrahepatic bile ducts with consequent periductular ﬁbrosis
was induced by injecting spleen and bone marrow cells of congenic B10.D2 mice into sublethally
irradiated BALB/c mice [111]. The close morphological similarities between this GVHD-model and
human PSC suggests that PSC and GVHD share immunological mechanisms [59]. Notably, loss/oblit-
eration of the peribiliary capillary plexus is also a hallmark of bile duct injury in the Abcb4/model.
Taken together, none of these model systems embody all the characteristics which one would
arrogate from an ideal PSC animal model but allows studying at least speciﬁc aspects of the still
enigmatic pathobiology of this devastating disease.
Summary
Despite recent advances in identifying important subgroups of PSC and learning important aspects
on their natural history as well as the increasing availability of animal models a clear and conclusive
M.J. Pollheimer et al. / Best Practice & Research Clinical Gastroenterology 25 (2011) 727–739736picture in regard to disease initiation and pathogenesis is still lacking. Our research agenda should
include (i) to identify and develop novel non-invasive tools for early PSC detection and (ii) to increase
the use of tests that are already available (e.g. MRCP). In patients with high suspicion of PSC, such as IBD
patients with a cholestatic enzyme pattern, systematically screening and repeated imaging usingMRCP
should be performed. Partially, the clinical impact of such an approach is already reﬂected by the
changing clinical picture of PSC, since patients are increasingly diagnosed in asymptomatic stages
[112]. Careful clinical observational studies of clearly deﬁned patient (sub)populations together with
novel animal models should signiﬁcantly speed up our gain in knowledge on the pathogenesis of PSC.
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